Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial*

“…Estudos clínicos duplo-cegos, controlados por placebo, em adultos e crianças maiores de 12 anos, indicam que a DL (5 mg/dia) é eficaz no tratamento da RA sazonal 26,31 e perene 32 e da RA intermitente 33 , melhorando todos os sintomas nasais, inclusive a obstrução 31,32 , os sintomas não nasais associados 32 e a qualidade de vida 31 . Em estudos multicêntricos, randomizados, duplo-cegos, controlados por placebo, realizados em adultos com urticária crônica idiopática, a DL (5 mg/dia) foi capaz de melhorar de forma significativa tanto os sintomas quanto a qualidade de vida dos pacientes 34,35 .…”

Section: Os Anti-histamínicos Mais Recentesunclassified

“…A DL não induz alterações clinicamente relevantes no intervalo QTc 34,36 , mesmo em indivíduos que utilizam drogas que usam a mesma via de metabolização hepáti-ca 22,23 . Apesar de seu potencial de interação com receptores muscarínicos, efeitos anticolinérgicos importantes não têm sido relatados 37 .…”

Section: Os Anti-histamínicos Mais Recentesunclassified

New antihistamines: a critical view

Camelo-Nunes¹

2006

J Pediatr (Rio J)

View full text Add to dashboard Cite

Objective: To perform a critical evaluation of the more recent H1 antihistamines and the various terms used to describe them, based on a review of evidence on their role in the treatment of allergic disorders.Sources: Original articles, reviews and consensus documents published from 1998 to 2006 and indexed in the MEDLINE and PubMed databases. Keyword: antihistamines.Summary of the findings: Second-generation antihistamines differ from first-generation ones because of their elevated specificity and affinity for peripheral H1 receptors and because of their lower penetration of the central nervous system (CNS), having fewer sedative effects as a result. Whilst second-generation antihistamines are in general better tolerated than their predecessors, some adverse effects, principally cardiotoxicity, have been observed with some of them. Over the last 20 years, new compounds with different pharmacokinetic properties have been synthesized. The majority of these exhibit antiinflammatory properties that are independent of their action on the H1 receptor. More recent improvements, generally in the form of active metabolites, led to the use of the term third-generation antihistamines. This term emerged spontaneously, with no clear definition of its meaning or clinical implications, creating great confusion among healthcare professionals. Conclusions:On the basis of the evidence on H1 antihistamines, none of them deserve the title third-generation antihistamine. As the Consensus Group on New Generation Antihistamines concluded, to merit this definition, a new class of antihistamines would have to demonstrate distinct clinical advantages over existing compounds and fulfill at least three prerequisites: they should be free from cardiotoxicity, drug interactions and effects on the CNS. J Pediatr (Rio J). 2006;82(5 Suppl):S173-80: Antihistamines, desloratadine, fexofenadine, levocetirizine, rupatadine. ResumoObjetivo: Avaliar criticamente os mais novos anti-histamínicos anti-H1 e os diferentes termos utilizados para denominá-los, com base na revisão de evidências sobre o papel dos anti-H1 no tratamento das doenças alérgicas.Fontes dos dados: Artigos originais, revisões e consensos indexados nos bancos de dados MEDLINE e PUBMED de 1998 a 2006. Palavra chave: anti-histamínicos.

show abstract

“…36 This is a welltolerated compound, with a minimal incidence of adverse effects that is comparable with placebo. [31][32][33]36 Desloratadine does not induce clinically relevant alterations to the QTc interval, 34,36 even in individuals given drugs that employ the same hepatic metabolism route. 22,23 Despite its potential for interaction with muscarinic receptors, no significant anticholinergic effects have been reported.…”

Section: More Recent Antihistaminesmentioning

confidence: 99%

“…31 In multicenter, randomized, doubleblind, placebo-controlled trials undertaken with adults with chronic idiopathic urticaria, DL (5 mg/day) was able to improve, to a significant extent, patients symptoms and their quality of life. 34,35 Desloratadine was shown to be safe and effective for the treatment of AR and chronic idiopathic urticaria in children aged 2 to 5 years and 6 to 11 years at dosages of 1.25 mg and 2.5 mg, respectively. 36 This is a welltolerated compound, with a minimal incidence of adverse effects that is comparable with placebo.…”

Section: More Recent Antihistaminesmentioning

confidence: 99%

Novos anti-histamínicos: uma visão crítica

Camelo-Nunes¹

2006

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

Objective: To perform a critical evaluation of the more recent H1 antihistamines and the various terms used to describe them, based on a review of evidence on their role in the treatment of allergic disorders.Sources: Original articles, reviews and consensus documents published from 1998 to 2006 and indexed in the MEDLINE and PubMed databases. Keyword: antihistamines.Summary of the findings: Second-generation antihistamines differ from first-generation ones because of their elevated specificity and affinity for peripheral H1 receptors and because of their lower penetration of the central nervous system (CNS), having fewer sedative effects as a result. Whilst second-generation antihistamines are in general better tolerated than their predecessors, some adverse effects, principally cardiotoxicity, have been observed with some of them. Over the last 20 years, new compounds with different pharmacokinetic properties have been synthesized. The majority of these exhibit anti-inflammatory properties that are independent of their action on the H1 receptor. More recent improvements, generally in the form of active metabolites, led to the use of the term third-generation antihistamines. This term emerged spontaneously, with no clear definition of its meaning or clinical implications, creating great confusion among healthcare professionals.Conclusions: On the basis of the evidence on H1 antihistamines, none of them deserve the title third-generation antihistamine. As the Consensus Group on New Generation Antihistamines concluded, to merit this definition, a new class of antihistamines would have to demonstrate distinct clinical advantages over existing compounds and fulfill at least three prerequisites: they should be free from cardiotoxicity, drug interactions and effects on the CNS. J Pediatr (Rio J). 2006;82(5 Suppl):S173-80: Antihistamines, desloratadine, fexofenadine, levocetirizine, rupatadine.

show abstract

Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial*

Cited by 93 publications

References 12 publications

Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria

Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria

New antihistamines: a critical view

Novos anti-histamínicos: uma visão crítica

Contact Info

Product

Resources

About